The Peptide Field. Semax: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/semax

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=semax#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Registered in Russia; no FDA-approved U.S. product or final 503A listing was identified as reviewed August 30, 2026

Exact product limits: Semax free base and Semax acetate are distinct chemical forms. A product name does not show which form it contains or whether it matches the material studied. N-acetyl Semax amidate is a different modified substance, not a Semax alias.

Human outcomes: Limited. Small and limited human studies do not establish the focus, memory, or treatment claims made online.

Body effects in people: Limited. FDA found no human pharmacokinetic studies, which measure how the body handles a drug. Human exposure and effects are not well characterized.

What the evidence shows: FDA reviewed Semax for reduced blood flow to the brain, migraine, and severe facial pain. They found too little proof for all three uses. A 1997 stroke study compared 30 Semax-treated people with 80 people who received standard care. Its abstract did not say how large the change was. A 2018 stroke study followed 110 people, but its abstract did not show random group assignment or blinding. The 12-person migraine and 25-person facial-pain groups had no control group or blinding.

What remains unknown: Studies do not show that Semax improves focus, memory, attention, or daily function. A 24-person study measured links on brain scans. It did not test thinking or daily function. FDA found no human study of how the body handles Semax. It found no safety data for use under the skin. Most reports gave few safety details. FDA warned about impurities, peptide clumps, immune reactions, and possible bleeding. No record shows an online product matches the form or study material.

Safety limits: This guide does not provide dosing, route, sourcing, product-selection, or treatment advice. A Russian registration or an advisory vote does not prove U.S. approval, product quality, or personal safety.

Approval claim: “Semax is FDA-approved in the United States.”
Verdict: Misleading. FDA says Semax free base and Semax acetate are not components of an FDA-approved drug. A drug registered in Russia does not create U.S. approval.
Evidence basis: Regulatory or product record. Scope: United States approval status as reviewed August 30, 2026.
Claim sources: https://www.fda.gov/media/193348/download https://precision.fda.gov/ginas/app/ui/substances/I5FAL2585H

Approval claim: “The advisory vote added Semax to the 503A list or approved it.”
Verdict: Misleading. RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.
Evidence basis: Regulatory or product record. Scope: The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval.
Claim sources: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193348/download https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA evaluation of Semax-related bulk drug substances. 2026. Accessed 2026-08-30. https://www.fda.gov/media/193348/download

U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. 2026. Accessed 2026-08-30. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

Electronic Code of Federal Regulations. 21 CFR 216.23 bulk drug substances list. 2026. Accessed 2026-08-30. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

U.S. Food and Drug Administration. FDA substance record for Semax free base. 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/I5FAL2585H

PubMed. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. 2018. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/29798983/

PubMed. Effectiveness of Semax in acute period of hemispheric ischemic stroke. 1997. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/11517472/

PubMed · Frontiers in Human Neuroscience. Resting brain-scan study in 24 healthy adults. 2018. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/30225715/

PubChem. N-acetyl Semax amidate identity record. 2026. Accessed 2026-08-30. https://pubchem.ncbi.nlm.nih.gov/compound/N-acetyl-semax-amidate

Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list. 2026. Accessed 2026-08-30. https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html

Keep the limits, review date, and sources with this record. Check the current source for changes.